Pulmonary Function Testing (PFT) is a crucial diagnostic tool in the field of pulmonology, offering invaluable insights into respiratory physiology and pathophysiology. The interpretation of PFT results, however, can be complex and challenging. This article seeks to provide a comprehensive guide for healthcare professionals to effectively interpret PFT results.
Interpreting PFTs begins with understanding the key parameters: Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the FEV1/FVC ratio. These measurements help to distinguish between obstructive and restrictive lung diseases. A reduced FEV1/FVC ratio indicates obstructive disease, while a normal or increased ratio with reduced volumes indicates restrictive disease.
Spirometry is the first-line PFT, providing vital information about airflow and lung volumes. The pattern of airflow limitation, the degree of reversibility, and the response to bronchodilators can all be assessed through spirometry. It is essential to evaluate these parameters in the context of the patient's clinical history and physical examination findings.
Additional tests, such as lung volume measurements and diffusing capacity for carbon monoxide (DLCO), provide further information about lung mechanics and gas exchange. Decreased DLCO can indicate interstitial lung disease or pulmonary vascular disease, while increased lung volumes can suggest air trapping or hyperinflation.
Interpreting PFTs is a critical skill for healthcare professionals managing patients with respiratory disorders. Understanding the basics of PFTs, interpreting spirometry, and comprehending lung volumes and gas exchange tests are essential steps in this process. By mastering these, clinicians can better diagnose, monitor, and manage their patients' respiratory conditions.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation